Participants 79 146 6
patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial
Participants 388 506 7
relationship of PlGF with cardiovascular outcomes in a large cohort of patients presenting across the spectrum of ACS.
Participants 528 685 4
baseline (n = 3,761) and at four-months (n = 3,369) in patients randomized to atorvastatin 80 mg or pravastatin 40 mg after ACS in the PROVE IT-TIMI 22 trial
Participants 1006 1080 3
patients with elevated baseline PlGF (Q1 vs. Q5: 7.0 vs. 11.6%, p = 0.029)
